This document is a publication of a United States Patent Application (US20260078202A1) from the USPTO, filed on April 25, 2025. The application, titled 'Orthogonal mutations for heterodimerization, antibody CH3 domains,' describes novel heterodimerizing domains, specifically for antibody CH3 domains, and their application in creating heterodimeric polypeptides and antibody constructs. The inventors listed are Jonathan Harry Davis and Nicholas M. Marshall.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it represents a new development in biotechnology and pharmaceutical research that may lead to future patent grants. Companies involved in antibody development or protein engineering should monitor this application and related patents for potential intellectual property considerations and future licensing opportunities.